Cheap generic of twice-yearly HIV prevention shot cleared for 120 countries
The US FDA has tentatively approved a generic lenacapavir expected to cost about $40 a year in low- and middle-income countries, compared with over $28,000 for the US brand.

A much cheaper version of lenacapavir, the HIV prevention injection given just twice a year, has been tentatively approved by the US Food and Drug Administration, ITV News reports, carrying an Associated Press story.
Made by India's Dr. Reddy's Laboratories with support from Unitaid, the Clinton Health Access Initiative and Wits RHI, the generic is expected to cost around $40 per person per year in 120 low- and middle-income countries. That is roughly the price of daily PrEP pills, while Gilead's brand-name version lists at about $28,000 a year in the US.
Some countries could receive doses within weeks, while others will need their own regulatory approvals first. The generic cannot be sold in the US while Gilead's patent is in force, and health groups say funding is still needed to reach everyone who could benefit.